Niagen Bioscience (NASDAQ:NAGE) Given New $9.00 Price Target at Canaccord Genuity Group

Niagen Bioscience (NASDAQ:NAGE) had its price objective cut by Canaccord Genuity Group from $10.00 to $9.00 in a research report report published on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also issued reports on the company. Freedom Capital raised Niagen Bioscience to a “strong-buy” rating in a research note on Monday, July 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a research note on Thursday, October 15th. Finally, Roth Capital reiterated a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Niagen Bioscience presently has an average rating of “Buy” and an average target price of $10.00.

Niagen Bioscience Stock Performance

Shares of NAGE opened at $2.33 on Friday. The stock has a market capitalization of $185.57 million, a P/E ratio of 12.95 and a beta of 2.02. The company’s fifty day moving average is $2.86 and its two-hundred day moving average is $3.93. Niagen Bioscience has a 1 year low of $2.32 and a 1 year high of $7.95.

Niagen Bioscience (NASDAQ:NAGE) last released its earnings results on Tuesday, August 4th. The company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. Niagen Bioscience had a return on equity of 17.95% and a net margin of 12.39%. The company had revenue of $29.78 million for the quarter, compared to analysts’ expectations of $29.95 million. Sell-side analysts predict that Niagen Bioscience will post 0.10 EPS for the current year.

Institutional Investors Weigh In On Niagen Bioscience

Large investors have recently modified their holdings of the stock. Gamco Investors INC. ET AL raised its holdings in shares of Niagen Bioscience by 2.5% during the first quarter. Gamco Investors INC. ET AL now owns 165,000 shares of the company’s stock valued at $728,000 after acquiring an additional 4,000 shares during the period. Teton Advisors LLC raised its holdings in shares of Niagen Bioscience by 20.0% during the 1st quarter. Teton Advisors LLC now owns 30,000 shares of the company’s stock valued at $132,000 after purchasing an additional 5,000 shares in the last quarter. Gabelli Funds LLC raised its holdings in Niagen Bioscience by 5.2% during the first quarter. Gabelli Funds LLC now owns 214,685 shares of the company’s stock valued at $947,000 after buying an additional 10,685 shares in the last quarter. Stoneridge Investment Partners LLC bought a new position in shares of Niagen Bioscience in the second quarter valued at approximately $49,000. Finally, Quantinno Capital Management LP lifted its position in Niagen Bioscience by 90.0% during the 1st quarter. Quantinno Capital Management LP now owns 50,946 shares of the company’s stock worth $225,000 after acquiring an additional 24,135 shares during the last quarter. 15.41% of the stock is owned by institutional investors.

About Niagen Bioscience

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.